Description
Dutanol (Dutasteride) 0.5 mg
Dutanol 0.5 mg is a dutasteride medicine presented as an oral capsule/tablet product name in some markets. Dutasteride is a prescription 5-alpha-reductase inhibitor used for benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It is not the same as finasteride, although both belong to the same therapeutic class.
Active Ingredient and Medicine Class
The verified active ingredient is dutasteride. It belongs to the class of 5-alpha-reductase inhibitors, specifically a dual inhibitor of type 1 and type 2 isoenzymes. By reducing the conversion of testosterone to dihydrotestosterone (DHT), it lowers androgen-driven prostate growth.
Established Medical Uses
Dutasteride is established for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate. Authoritative prescribing information describes benefits such as improvement in urinary symptoms, reduction in prostate size, and reduction in the risk of acute urinary retention and BPH-related surgery.
Some regulatory documents also describe use with an alpha-adrenergic antagonist in combination treatment for men with BPH. Dutasteride is not approved as a prostate cancer treatment, and any effect on prostate cancer detection or risk must be interpreted cautiously.
How It Works
Dutasteride blocks the enzyme 5-alpha-reductase, which converts testosterone into DHT. DHT is a more potent androgen in prostate tissue and is a major driver of prostate enlargement. By lowering DHT levels, dutasteride can gradually reduce prostate volume and improve lower urinary tract symptoms linked to BPH.
Important Safety Information
Dutasteride is contraindicated in pregnancy and should not be used by women who are or may become pregnant, because exposure may harm a developing male fetus. The capsule contents may be absorbed through the skin if damaged, so handling precautions are important.
Important warnings in prescribing information include the effect on prostate-specific antigen (PSA), which falls by about half during treatment and can complicate interpretation of prostate cancer screening. Dutasteride is extensively metabolized in the liver, so caution is advised in hepatic impairment. Clinically significant interactions may occur with potent chronic CYP3A4 inhibitors such as ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, troleandomycin and ciprofloxacin.
Possible Side Effects
Commonly reported adverse effects include impotence/erectile dysfunction, decreased libido, ejaculation disorders, and breast disorders such as enlargement or tenderness. Dizziness has been reported more often when dutasteride is used together with tamsulosin.
Less common but important concerns include persistent sexual adverse effects in some patients, breast changes that warrant medical evaluation, and the need to consider prostate cancer assessment carefully if PSA is being monitored.
Scientific Evidence
Clinical trial and review evidence consistently shows that dutasteride improves urinary symptom scores, increases urinary flow, and reduces prostate volume in men with BPH. Longer-term studies also suggest a reduced risk of acute urinary retention and BPH-related surgery compared with placebo. Meta-analyses generally support these benefits, while noting an increased rate of sexual adverse effects compared with placebo.
Scientific studies have also shown that dutasteride causes strong and sustained suppression of DHT, which explains its clinical effect on prostate tissue. Evidence comparing dutasteride with finasteride suggests broadly similar efficacy and safety for BPH, with no clear superiority across all outcomes.
Medical Information Notice
This summary is based on officially available prescribing information and selected peer-reviewed literature available at the time of review. It is intended for educational use and does not replace the official patient leaflet or an individual assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration AVODART (dutasteride) prescribing information. View official FDA label
- U.S. Food and Drug Administration Dutasteride capsules prescribing information. View official FDA labeling
- Claus G Roehrborn et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology, 2004. View scientific article
- Andrew Thomson Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia. Core Evidence, 2005. View scientific article
